Shilpa Pharma Lifesciences Ltd, Unit 2, Raichur, Karnataka has cleared the ANVISA-Brazil GMP inspection

Shilpa Medicare Limited's 100% subsidiary, Shilpa Pharma Lifesciences Limited'sActive Pharmaceutical Ingredient (API) manufacturing facility, Unit II, situated at Raichur in Karnataka state has undergone a GMP inspection by ANVISA-Brazil from April 15-April 19, 2024.

Following a successful inspection, the Unit has been issued GMP Certification from ANVISA-Brazil.

The facility is involved in manufacturing various oncology and nononcology APIs. The company remains committed to maintain the GMP status and quality standards as per the expectations and standards of Global Regulatory Authorities.

Shares of Shilpa Medicare Limited was last trading in BSE at Rs. 658.10 as compared to the previous close of Rs. 667.05. The total number of shares traded during the day was 12154 in over 1126 trades.

The stock hit an intraday high of Rs. 676.30 and intraday low of 656.50. The net turnover during the day was Rs. 8119164.00.

Source : Equity Bulls

Keywords

ShilpaMedicare INE790G01031 ShilpaPharmaLifesciences API ManufacturingFacility Unit2 Raichur GMPInspection ANVISA Brazil